Core Viewpoint - The article highlights the recent IPO of three companies on the Hong Kong Stock Exchange, with a particular focus on药捷安康, which experienced a significant stock price increase on its debut despite being in a loss-making position and lacking approved products for commercial sale [1][2]. Group 1: Company Overview - 药捷安康 is a clinical-stage biopharmaceutical company focused on developing innovative small molecule therapies for cancer, inflammation, and cardiovascular metabolic diseases [1]. - The company was founded in 2014 and had previously attempted to list on the Hong Kong Stock Exchange in 2021 but did not proceed [3]. Group 2: IPO Details - 药捷安康 priced its shares at HKD 13.15, issuing 15.281 million shares, with a public offering oversubscription rate of 3,419.87 times [2]. - The company raised approximately HKD 1.61 billion from the IPO, with plans to allocate 90% of the net proceeds to fund a multi-regional Phase III clinical trial for its core product, Tinengotinib [4]. Group 3: Financial Performance - 药捷安康 reported cumulative losses exceeding HKD 618 million over the past two years, with projected revenues of HKD 1.18 million in 2023 and zero in 2024, alongside significant R&D costs [3]. - The company has utilized about 72% of the funds raised from previous investments prior to the IPO [3]. Group 4: Future Plans - Following the IPO, 药捷安康 aims to accelerate its internationalization and commercialization efforts, including the establishment of an internal commercial team in China [2].
港股创新药仍获追捧：亏损中的药捷安康上市首日涨超70%，61岁董事长吴永谦上台敲锣